Business Wire

AUTODOC

26.3.2020 18:38:07 CET | Business Wire | Press release

Share
Autodoc donates EUR 50,000 for coronavirus research

Autodoc, Europe’s largest online retailer of car spare parts, is donating EUR 50,000 to the Stiftung Universitätsmedizin Essen foundation to support the fight against COVID-19. The researchers are studying the biology of the virus together with Chinese colleagues in a laboratory in Wuhan, China. The aim is to develop therapeutic options and preventive measures. As an internationally active company, Autodoc would like to become involved at a global level in the fight against the current pandemic.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200326005597/en/

Autodoc GmbH, based in Berlin, is an international company with online shops in 26 European countries. The employees come from all over the world. The current crisis also affects Autodoc employees, customers and suppliers to a high degree. Autodoc would like to take its responsibility as a company and actively participate in the fight against COVID-19. To this end, Autodoc is supporting researchers at the Universitätsmedizin Essen medical center and the Union Hospital in Wuhan in their search for special treatments against the virus.

According to Alexej Erdle, managing partner of Autodoc GmbH, “The corona crisis is a global pandemic that affects us all. We are an international company. That is why we feel a clear responsibility here to contribute to solving this crisis. Every day we see what can be achieved when people from different countries work together, just as the researchers from Essen and Wuhan are doing. Supporting their work is now the best way for us to do something that helps people all over the world, i.e. to fight this pandemic. With this donation, we want to set an example so that every individual as well as every company can think about how to get involved within the scope of their respective possibilities so that we can succeed in overcoming this challenge together.

Researchers against a global pandemic

Since the end of December 2019, the novel coronavirus, SARS-CoV-2, has been spreading at high speed. It is the trigger of the COVID-19 disease. The Institute of Virology and the Clinic for Infectiology at the Universitätsmedizin Essen medical center and the Clinic for Infectious Diseases at the Union Hospital in Wuhan have been working closely together for many years. In 2017, a joint research laboratory was founded in Wuhan. Numerous data and samples have been collected and recorded there since the beginning of the COVID-19 pandemic. Due to the number of cases in China, this results in a much larger database than is currently the case in Germany, for example. The laboratory is already in operation and well equipped, but money is still urgently needed to cover the running costs for material and personnel. Autodoc is now supporting the researchers’ work with a sum of EUR 50,000.

Jorit Ness, Managing Director of the University Medical Foundation, is very grateful for the support: “In the current situation, rapid help – which is at the same time sustainable – is essential. Thanks to the research cooperation between Essen and Wuhan, which has been in place for years, professional and established structures are now in place and can be used immediately. It is now important to make additional funds available for the evaluation of the extraordinarily large amounts of data and samples of disease cases. With the donation from Autodoc GmbH we have come a big step closer to our goal”.

Social commitment

Since its foundation in 2008, Autodoc has seen itself as an active part of society and is committed both ideologically and financially to helping disadvantaged social groups. Autodoc therefore regularly supports local initiatives in various European countries.

If you would like to support the research work in Essen and Wuhan, please visit https://www.universitaetsmedizin.de/forschung/corona/ and make a donation online. Or donate directly to:

Stiftung Universitätsmedizin Essen
Hufelandstraße 55
45147 Essen, Germany
E-mail: info@universitaetsmedizin.de
Internet: https://www.universitaetsmedizin.de/
Donation account:
IBAN: DE 0937 0205 0005 0005 0005
BIC: BFSWDE33
Reference: corona research

Autodoc GmbH – a brief profile

Autodoc GmbH is Europe’s leading online dealer for automotive spare parts. As the fastest-growing company in this sector with a 63% growth in turnover in the 2018 financial year to around EUR 415 million (2017: EUR 254 million), Autodoc is aiming to further expand its position. Thanks to its successful expansion, Autodoc is now represented in 25 other European countries in addition to Germany. Autodoc pursues a strong customer focus through social media activities, technical support in the respective national language and demand-oriented product range composition with currently almost 2.5 million products from 545 brand manufacturers for 128 car brands. The online retailer offers a wide range of products from brake systems, body parts, shock absorbers and springs, exhaust systems, interior elements, steering systems and clutches to air conditioning systems, heaters, repair kits and engine oil. In June 2018, the company celebrated its tenth anniversary. Autodoc GmbH is based in the Berlin district of Lichtenberg and is fully owner-managed. In May 2019, the company opened a representative office on Kurfürstendamm in addition to its headquarters.

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release

Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release

Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly

Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release

Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial

Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release

Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye